The company reported worldwide sales of $5.15 billion in the second quarter of 2008, an increase of 11%, compared with $4.63 billion in the corresponding period of 2007.
For the first six months of 2008, worldwide reported and pro forma sales increased 12% to $9.96 billion, compared with sales for the same period in 2007. Reported net income and earnings per share were $2.02 billion and $1.85, respectively.
John Lechleiter, Lilly’s president and CEO, said: “Lilly continued to deliver solid financial results in the second quarter, including double-digit growth in sales and earnings. Our newer products, including Cymbalta, Cialis and Alimta, continued to perform exceptionally well, while our diabetes care franchise has made good progress.
“During the quarter, we also remained engaged in business development activities designed to strengthen our R&D capabilities, resulting in both the in-licensing deal with TransPharma and the announced acquisition of SGX Pharmaceuticals.”